tbuckley/cabot-search huggingface dataset:
Targeting brain Renin-Angiotensin System for the prevention and treatment of Alzheimer’s disease: Past, present and future
Authors: Filipa Gouveia, Antoni Camins, Miren Ettcheto, Joana Bicker, Amílcar Falcão, M. Teresa Cruz, Ana Fortuna
Journal: Ageing Research Reviews (2022)

Alzheimer's disease (AD) is a well-known neurodegenerative disease characterized by the presence of two main hallmarks – Tau hyperphosphorylation and Aβ deposits. Notwithstanding, in the last few years the scientific evidence about the drivers of AD have been changing and nowadays age-related vascular alterations and several cardiovascular risk factors have been shown to trigger the development of AD. In this context, drugs targeting the Renin Angiotensin System (RAS), commonly used for the treatment of hypertension, are evidencing a high potential to delay AD development due to their action on brain RAS. Indeed, the ACE 1/Ang II/AT1R axis is believed to be upregulated in AD and to be responsible for deleterious effects such as increased oxidative stress, neuroinflammation, blood-brain barrier (BBB) hyperpermeability, astrocytes dysfunction and a decrease in cerebral blood flow. In contrast, the alternative axis – ACE 1/Ang II/AT2R; ACE 2/Ang (1−7)/MasR; Ang IV/ AT4R(IRAP) – seems to counterbalance the deleterious effects of the principal axis and to exert beneficial effects on memory and cognition. Accordingly, retrospective studies demonstrate a reduced risk of developing AD among people taking RAS medication as well as several in vitro and in vivo pre-clinical studies as it is herein critically reviewed. In this review, we first revise, at a glance, the pathophysiology of AD focused on its classic hallmarks. Secondly, an overview about the impact of the RAS on the pathophysiology of AD is also provided, focused on their four essential axes ACE 1/Ang II/AT2R; ACE 2/Ang (1−7)/MasR; Ang IV/ AT4R(IRAP) and ACE 1/Ang II/AT1R. Finally, the therapeutic potential of available drugs targeting RAS on AD, namely angiotensin II receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACEIs), is highlighted and data supporting this hope will be presented, from in vitro and in vivo pre-clinical to clinical studies.
From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit
Authors: Toni K. Choueiri, Laurence Albiges, Michael B. Atkins, Ziad Bakouny, Gennady Bratslavsky, David A. Braun, Naomi B. Haas, John B.A.G. Haanen, A. Ari Hakimi, Michael A.S. Jewett, Eric Jonasch, William G. Kaelin, Payal Kapur, Chris Labaki, Bryan Lewis, David F. McDermott, Sumanta K. Pal, Kevin Pels, Susan Poteat, Thomas Powles, W. Kimryn Rathmell, Brian I. Rini, Sabina Signoretti, Nizar M. Tannir, Robert G. Uzzo, Hans J. Hammers
Journal: Clinical Cancer Research (2021)

The second Kidney Cancer Research Summit was held virtually in October 2020. The meeting gathered worldwide experts in the field of kidney cancer, including basic, translational, and clinical scientists as well as patient advocates. Novel studies were presented, addressing areas of unmet need related to different topics. These include novel metabolic targets, promising immunotherapeutic regimens, predictive genomic and transcriptomic biomarkers, and variant histologies of renal cell carcinoma (RCC). With the development of pioneering technologies, and an unprecedented commitment to kidney cancer research, the field has tremendously evolved. This perspective aims to summarize the different sessions of the conference, outline major advances in the understanding of RCC and discuss current challenges faced by the field.
Gated Tomographic Radionuclide Angiography Using 3D-Ring CZT StarGuide SPECT/CT Head-To-Head Comparison With a Cardiac-Dedicated CZT Camera
Authors: Thibaut Carsuzaa, Frédérique Thibault, Matthieu Bailly
Journal: Clinical Nuclear Medicine (2022)

Gated tomographic radionuclide angiography can assess and monitor left cardiac function. Dedicated cardiac CZT cameras have enabled dose reduction and quicker acquisitions. New 3D-ring CZT general purpose systems are now available. We report 50 patients who underwent a 7-minute acquisition on a cardiac-dedicated CZT camera and 9 minutes on a new 3D-ring CZT system after mean injection of 321.4 ± 55.9 MBq 99mTc-labelled human serum albumin. There was no significant difference in left ventricular volumes, and left and right ventricular ejection fractions. These preliminary results seem to validate the use of 3D-ring CZT system for LEVF and cardiac function evaluation.
Molecular Characterization of<i>KRAS</i>Wild-type Tumors in Patients with Pancreatic Adenocarcinoma
Authors: Philip A. Philip, Ibrahim Azar, Joanne Xiu, Michael J. Hall, Andrew Eugene Hendifar, Emil Lou, Jimmy J. Hwang, Jun Gong, Rebecca Feldman, Michelle Ellis, Phil Stafford, David Spetzler, Moh'd M. Khushman, Davendra Sohal, A. Craig Lockhart, Benjamin A. Weinberg, Wafik S. El-Deiry, John Marshall, Anthony F. Shields, W. Michael Korn
Journal: Clinical Cancer Research (2022)

KRAS mutation (MT) is a major oncogenic driver in pancreatic ductal adenocarcinoma (PDAC). A small subset of PDACs harbor KRAS wild-type (WT). We aim to characterize the molecular profiles of KRAS WT PDAC to uncover new pathogenic drivers and offer targeted treatments.
Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review
Authors: Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng
Journal: Clinical and Molecular Hepatology (2022)

Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease with a global prevalence of about 55% in people with type 2 diabetes mellitus (T2DM). T2DM, obesity and NAFLD are three closely inter-related pathological conditions. In addition, T2DM is one of the strongest clinical risk factors for the faster progression of NAFLD to non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Increasing evidence suggests that newer classes of glucose-lowering drugs, such as peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors or sodium-glucose cotransporter-2 inhibitors, could reduce the rates of NAFLD progression. This narrative review aims to briefly summarize the recent results from randomized controlled trials testing the efficacy and safety of old and new glucose-lowering drugs for the treatment of NAFLD or NASH in adults both with and without coexisting T2DM.
IMPACT OF CORONARY ARTERY DISEASE ON CLINICAL OUTCOMES AFTER TAVR: INSIGHTS FROM THE BRAVO-3 RANDOMIZED TRIAL
Authors: Daniel Feldman, Davide Cao, Johny Nicolas, Christian Hengstenberg, Zhongie Zhang, Samantha Sartori, Frans Beerkens, Carlo Andrea Pivato, Mauro Chiarito, Mohan Satish, Davis B. Jones, Divya Iyer, David Power, Huazhen Chen, Anton Camaj, Victor Razuk, Anastasios Roumeliotis, Raban V. Jeger, Roberto Violini, Markus Ferrari, Roxana Mehran, George D. Dangas
Journal: Journal of the American College of Cardiology (2022)
Increased CD8+ T-cell Infiltration and Efficacy for Multikinase Inhibitors After PD-1 Blockade in Hepatocellular Carcinoma
Authors: Hiroto Kikuchi, Aya Matsui, Satoru Morita, Zohreh Amoozgar, Koetsu Inoue, Zhiping Ruan, Daniel Staiculescu, Jeffrey Sum-Lung Wong, Peigen Huang, Thomas Yau, Rakesh K Jain, Dan G Duda
Journal: JNCI Journal of the National Cancer Institute (2022)

Abstract Immune checkpoint blockade combined with antiangiogenic therapy induces vascular normalization and antitumor immunity and is efficacious in hepatocellular carcinoma (HCC); but whether and how initial immunotherapy affects the efficacy of subsequent antiangiogenic therapy are unknown. We evaluated a cohort of HCC patients (n = 25) who received the pan–vascular endothelial growth factor receptor multikinase inhibitor sorafenib after initial therapy with an antiprogrammed cell death protein (PD)–1 antibody and found superior outcomes in these patients (12% overall response rate to sorafenib and a median overall survival of 12.1 months). To prove this potential benefit, we examined the impact of an anti–PD-1 antibody on response to subsequent sorafenib treatment in orthotopic models of murine HCC. Prior anti–PD-1 antibody treatment amplified HCC response to sorafenib therapy and increased survival (n = 8-9 mice per group, hazard ratio = 0.28, 95% confidence interval = 0.09 to 0.91; 2-sided P = .04). Anti–PD-1 therapy showed angioprotective effects on HCC vessels to subsequent sorafenib treatment, which enhanced the benefit of this therapy sequence in a CD8+ T-cell–dependent manner. This priming approach using immunotherapy provides an immediately translatable strategy for effective HCC treatment while reducing drug exposure.
Abstract P1-08-23: Androgen receptor as predictive marker for pathologic complete response in breast cancer with neoadjuvant chemotherapy
Authors: Eun-Gyeong Lee, Dong-Eun Lee, Jai Hong Han, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Youngmee Kwon, Hyun Hee Kim, Hee Jung Chae, Sung Hoon Sim, Keun Seok Lee, So-Youn Jung
Journal: Cancer Research (2022)

Abstract Background: Androgen receptors (AR) has emerged as a prognostic factor predicting survival and recurrence in breast cancer. However, the role of AR as a predictor of pathological complete response (pCR) rate after neoadjuvant chemotherapy by subtypes is unclear. This study aimed to investigate according to AR in breast cancer patients undergoing neoadjuvant chemotherapy as a predictor. Furthermore, we estimated the relationship between AR expression and clinicopathological factors. Method: We identified 624 breast cancer patients who underwent surgery after neoadjuvant chemotherapy at the National Cancer Center from April 2016 to October 2019. We retrospectively collected the medial records that the clinicopathologic information and AR expression analyzed according to cancer stage, hormonal receptor status, HER2 status, tumor subtype, pCR. Results: Among the 624 breast cancer patients, 529 (84.8%) were AR positive patients and 95 (15.2%) were AR negative patients. The mean age of the patients was 50.0 years. The rate of pCR was 31.4% (196/624). AR negative patients had significantly high rate of pCR than AR positive patients. (AR (-) 43.2% vs. AR (+) 29.3%, p = 0.0074). AR positive patients showed more ER positivity, PR positivity, HER2 positivity and luminal A subtype. A higher proportion of AR positive patients compared to AR negative patients received target therapy and hormonal therapy (target therapy, AR (-) 15.8% vs. AR (+) 43.9%, hormonal therapy, 14.7% vs. 71.0%, p &amp;lt;.0001). The tumor factors associated with pCR were early stage, histologic grade 3, ER negativity, PR negativity, AR positivity, HER2 positivity, and high ki-67%. According to subtypes of tumor, the correlation between AR expression and pCR was. significantly higher in AR negative luminal A type (AR (-) 28.57% vs. AR (+) 7.26%, p =0.0215). The other subtypes did not show a statistically significant difference. Conclusion: This study shows that AR expression is predominant in luminal A subtype. When determining neoadjuvant chemotherapy in luminal A subtype, AR expression can be considered as a pCR predictive marker. Citation Format: Eun-Gyeong Lee, Dong-Eun Lee, Jai Hong Han, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Youngmee Kwon, Hyun Hee Kim, Hee Jung Chae, Sung Hoon Sim, Keun Seok Lee, So-Youn Jung. Androgen receptor as predictive marker for pathologic complete response in breast cancer with neoadjuvant chemotherapy [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-08-23.
Ticagrelor Versus Clopidogrel in the treatment of Elderly Chinese Chronic Total Occlusion Patients Undergoing Percutaneous Coronary Intervention
Authors: Kun Lian, Qingyi Wang, Chengxiang Li, Peng Han, Ying Liang, Suining Xu, Shuai Zhao, Yan Chen, Ziwei Wang, Yuhao Chen, Boda Zhu, Zhilin Sha, Anxin Shen, Feng Tao, Qin Wang, Qiong Wang, Genrui Chen, Zhijun Tan, Li Yang, Haokao Gao
Journal: Clinical Cardiology and Cardiovascular Interventions (2022)

Background: Taking thrombosis and bleeding risks into consideration, little real world study data is available to dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in elderly Chinese chronic total occlusion (CTO) patients. Objective: This study was designed to investigate the effectiveness and safety of Ticagrelor in comparison with Clopidogrel as an add-on therapy to Aspirin for elderly Chinese CTO patients who underwent elective PCI. Materials and Methods: We retrospectively enrolled 504 CTO patients (aged ≥75 years) who received PCI from December 2009 to May 2020 and DAPT for up to 12 months. The effectiveness endpoints were evaluated by major adverse cardiac events (MACE) including all-cause death, nonfatal myocardial infarction (MI) and clinically driven revascularization. The safety endpoints were recorded as the incidence of Bleeding Academic Research Consortium (BARC) bleeding. Results: Patients in Clopidogrel group, as was evidenced in our study, were older, and had a higher percentage of BMI, diastolic blood pressure and HDL-C than those in Ticagrelor group. Clopidogrel group had a lower percentage of hyperlipidemia, prior PCI, glucose, TG and LDL-C. No significant difference was found as to the Angiographic and procedural characteristics (P＞0.05 for all). After 12 months' follow-up, the incidence of MACE (12.19% vs. 11.04%, P=0.763) and bleeding (9.38% vs. 13.64%, P=0.205) showed no significant difference. After clinical characteristics balanced matching by inverse probability of treatment weighting (IPTW) model, we found that Ticagrelor had an unfavorable effect on reducing the incidence of bleeding with the IPTW model (IPTW-OR, 1.81, 95% CI: 1.18-2.76, P=0.006). Conclusions: Clopidogrel and Ticagrelor present similar effectiveness and safety to elderly Chinese CTO-PCI patients, yet Ticagrelor should be prescribed with caution to patients with a high bleeding risk.
Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis
Authors: Darren Jun Hao Tan, Cheng Han Ng, Snow Yunni Lin, Xin Hui Pan, Phoebe Tay, Wen Hui Lim, Margaret Teng, Nicholas Syn, Grace Lim, Jie Ning Yong, Jingxuan Quek, Jieling Xiao, Yock Young Dan, Mohammad Shadab Siddiqui, Arun J Sanyal, Mark D Muthiah, Rohit Loomba, Daniel Q Huang
Journal: The Lancet Oncology (2022)

The clinical presentation and outcomes of non-alcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma are unclear when compared with hepatocellular carcinoma due to other causes. We aimed to establish the prevalence, clinical features, surveillance rates, treatment allocation, and outcomes of NAFLD-related hepatocellular carcinoma.
HEMODYNAMIC PERFORMANCE OF 16-20MM EXTRACARDIAC GORETEX CONDUITS IN ADOLESCENT FONTAN PATIENTS AT REST AND WITH SIMULATED EXERCISE
Authors: Friso Rijnberg, Luca van 't Hul, Mark Hazekamp, Pieter van den Boogaard, Joe Juffermans, Hildo J. Lamb, Covadonga Terol Espinosa de Los Monteros, Lucia Kroft, Sasa Kenjeres, Saskia Le Cessie, Monique Jongbloed, Jos Westenberg, Arno Roest, Jolanda Wentzel
Journal: Journal of the American College of Cardiology (2022)
Prevalence of Surgical Procedures at Symptomatic Onset of Prion Disease
Authors: Amanda L. Porter, Christian C. Prusinski, Evelyn Lazar, Clara Yuh, Robert C. Bucelli, Brian S. Appleby, Gregory S. Day
Journal: JAMA Network Open (2022)

Mann-Whitney U tests for continuous variables to evaluate the association between patient-specific factors and procedures.Significance was set at P < .10due to the exploratory nature of this analysis.
THE IMPACT OF LIFESTYLE AND SOCIOECONOMIC FACTORS ON THE ASSOCIATION BETWEEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND MAJOR ADVERSE CARDIOVASCULAR EVENTS: A POPULATION-BASED COHORT STUDY
Authors: Kasper Bonnesen, Vera Ehrenstein, Ola Ekholm, Lars Pedersen, Henrik T. Sørensen, Morten Schmidt
Journal: Journal of the American College of Cardiology (2022)
Retracted: PTEN loss drives resistance to the neddylation inhibitor MLN4924 in glioblastoma and can be overcome with TOP2A inhibitors
Authors: Shayesteh R Ferdosi, Brett Taylor, Matthew Lee, Nanyun Tang, Sen Peng, Rita Bybee, George Reid, Lauren Hartman, Krystine Garcia-Mansfield, Ritin Sharma, Patrick Pirrotte, Jianhui Ma, Alison D Parisian, Frank Furnari, Harshil D Dhruv, Michael E Berens
Journal: Neuro-Oncology (2022)

Neddylation inhibition, affecting posttranslational protein function and turnover, is a promising therapeutic approach to cancer. We report vulnerability to MLN4924 or pevonedistat (a neddylation inhibitor) in a subset of glioblastoma (GBM) preclinical models and identify biomarkers, mechanisms, and signatures of differential response.
Association of Medicare-Medicaid Dual Eligibility and Race and Ethnicity With Ischemic Stroke Severity
Authors: Pamela R. Bosch, Amol M. Karmarkar, Indrakshi Roy, Corey R. Fehnel, Robert E. Burke, Amit Kumar
Journal: JAMA Network Open (2022)

Black and Hispanic US residents are disproportionately affected by stroke incidence, and patients with dual eligibility for Medicare and Medicaid may be predisposed to more severe strokes. Little is known about differences in stroke severity for individuals with dual eligibility, Black individuals, and Hispanic individuals, but understanding hospital admission stroke severity is the first important step for focusing strategies to reduce disparities in stroke care and outcomes.
The International Association for the Study of Lung Cancer Staging Project: Methods and Guiding Principles for the Development of the Ninth Edition TNM Classification
Authors: Frank C. Detterbeck, Katherine K. Nishimura, Vanessa J. Cilento, Meredith Giuliani, Mirella Marino, Raymond U. Osarogiagbon, Ramon Rami-Porta, Valerie W. Rusch, Hisao Asamura
Journal: Journal of Thoracic Oncology (2022)
CARDIORESPIRATORY INDICES IN RELATION TO MARKERS OF PSYCHOPATHOLOGY AND NEUROCOGNITIVE FUNCTION IN POST SARS-COV-2 INFECTED SUBJECTS
Authors: Christos Fragoulis, Maria Kariori, Andreas G. Prentakis, Evangelia Kontogianni, Ioannis Leontsinis, Aggeliki Valatsou, Dimitris Konstantinidis, Maria Pirounaki, Constadina Aggeli, Christina Chrysochoou, Antonios Politis, Dimitrios Vassilopoulos, Konstantinos Tsioufis
Journal: Journal of the American College of Cardiology (2022)
ATRIAL FIBRILLATION AS PREDICTOR OF OUTCOMES IN PATIENTS WITH SPONTANEOUS CORONARY ARTERY DISSECTION
Authors: Sundeep Kumar, Ali Ghani, Ruthvik Srinivasamurthy, Akhil Mogalapalli, Sarika Kumari, Hiren R. Patel, Ziad SayedAhmad, Sayed Tahir Hussain, Ammar Nasir, Deana Mikhalkova, Philip L. Mar
Journal: Journal of the American College of Cardiology (2022)
ATP7B gene therapy of autologous reprogrammed hepatocytes alleviates copper accumulation in a mouse model of Wilson’s disease
Authors: Hongxia Cai, Xing Cheng, Xiao‐Ping Wang
Journal: Hepatology (2022)

Abstract Background and Aims Wilson’s disease (WD) is a rare hereditary disorder due to ATP7B gene mutation, causing pathologic copper storage mainly in the liver and neurological systems. Hepatocyte transplantation showed therapeutic potential; however, this strategy is often hindered by a shortage of quality donor cells and by allogeneic immune rejection. In this study, we aimed to evaluate the function and efficacy of autologous reprogrammed, ATP7B gene‐restored hepatocytes using a mouse model of WD. Approach and Results Sufficient liver progenitor cells (LPCs) were harvested by reprogramming hepatocytes from ATP7B−/− mice with small molecules, which exhibited strong proliferation and hepatic differentiation capacity in vitro. After lentivirus‐mediated mini ATP7B gene transfection and redifferentiation, functional LPC‐ATP7B‐derived hepatocytes (LPC‐ATP7B‐Heps) were developed. RNA sequencing data showed that, compared with LPC–green fluorescent protein–Heps (LPC‐GFP‐Heps) with enrichment of genes that were mainly in pathways of oxidative stress and cell apoptosis, in LPC‐ATP7B‐Heps under high copper stress, copper ion binding and cell proliferation pathways were enriched. LPC‐ATP7B‐Heps transplantation into ATP7B−/− mice alleviated deposition of excess liver copper with its associated inflammation and fibrosis, comparable with those observed using normal primary hepatocytes at 4 months after transplantation. Conclusions We established a system of autologous reprogrammed WD hepatocytes and achieved ATP7B gene therapy in vitro. LPC‐ATP7B‐Heps transplantation demonstrated therapeutic efficacy on copper homeostasis in a mouse model of WD.
ATRIOVENTRICULAR NODAL RE-ENTRANT TACHYCARDIA AS AN INITIAL MANIFESTATION OF CARDIAC AMYLOIDOSIS
Authors: Luis Antonio Jimenez Ruan, Jorge Sanchez-Nieto, Alejandra Carolina González Mira, Clara Esperanza Hernández Orellana, Rodrigo Soria García, Jose Luis Briseño De La Cruz
Journal: Journal of the American College of Cardiology (2022)
Palliative Care Is the Umbrella, Not the Rain—A Metaphor to Guide Conversations in Advanced Cancer
Authors: Camilla Zimmermann, Jean Mathews
Journal: JAMA Oncology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
A Radiation Oncologist’s Experience With Medical Aid in Dying
Authors: Santosh V. Yajnik
Journal: JAMA Oncology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
NEUTROPHIL-LYMPHOCYTE RATIO, BLOOD PRESSURE VARIABILITY AND INCIDENT CARDIOVASCULAR EVENTS IN PATIENTS ATTENDING FAMILY MEDICINE CLINICS
Authors: Yan Hiu Athena Lee, Jiandong Zhou, Jeremy Hui, Oscar Zhou, Teddy Lee, Keith Leung, Abraham Wai, Sharen Lee, Fang Zhou Liu, Tong Liu, Carlin Chang, Bernard Cheung, Qingpeng Zhang, Gary Tse
Journal: Journal of the American College of Cardiology (2022)